Key result
Pharmacological therapies including statins, ezetimibe, bempedoic acid, and PCSK9 inhibitors are effective for reducing LDL-C, though cost, injection reluctance, and long-term adherence remain challenges.
This review summarizes current and emerging pharmacological options for LDL-C reduction, highlighting the potential of novel oral therapies to overcome barriers associated with injectable PCSK9 inhibitors.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Brian Tomlinson (2026) conducted a review in Hypercholesterolaemia and mixed dyslipidaemia. Pharmacological LDL-C lowering therapies (statins, ezetimibe, bempedoic acid, PCSK9 inhibitors) was evaluated. Pharmacological therapies including statins, ezetimibe, bempedoic acid, and PCSK9 inhibitors are effective for reducing LDL-C, though cost, injection reluctance, and long-term adherence remain challenges.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More from Expert Opinion on Pharmacotherapy